瑞德希韋Lancet論文：（隨即雙盲安慰劑對照）重症無效

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.

However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.早期治療縮短恢復時間有待進一步驗證。

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext

明天股票怎麼走？糾結了